Hims & Hers reports mixed first quarter results

Hims & Hers Health posted a revenue miss in the first quarter amid margin pressures.

The company is shifting away from compounded GLP-1 medications toward branded partnerships with Novo Nordisk and Eli Lilly. This change is expected to affect near-term margins while lowering legal risks associated with compounding.

संबंधित लेख

Hermès reported a 6% revenue increase in the first quarter of 2026, driven entirely by higher prices amid flat volume growth. The Middle East conflict led to a 6% sales drop in that region and a double-digit decline in its US-traded shares. Analysts view the sell-off as overdone, presenting a buying opportunity for long-term investors.

AI द्वारा रिपोर्ट किया गया

HLS Therapeutics Inc. (TSX: HLS:CA) has published a slide deck for its 2025 fourth-quarter earnings call, released on March 13, 2026, following an earnings summary dated March 12, 2026.

Palantir Technologies Inc. delivered exceptional first-quarter results, with revenue exceeding consensus estimates by 6% and earnings per share nearly 20% above forecasts. The company's revenue grew over 80% year-over-year, outpacing most tech peers. Despite the strong performance, shares did not rally amid valuation concerns.

AI द्वारा रिपोर्ट किया गया

LVMH announced first-quarter sales rose 1% organically to €19.12 billion. Fashion and leather goods sales fell 2% to €9.25 billion, better than the prior quarter but below expectations. The Middle East conflict impacted growth by about 1 percentage point.

 

 

 

यह वेबसाइट कुकीज़ का उपयोग करती है

हम अपनी साइट को बेहतर बनाने के लिए विश्लेषण के लिए कुकीज़ का उपयोग करते हैं। अधिक जानकारी के लिए हमारी गोपनीयता नीति पढ़ें।
अस्वीकार करें